Canada Pension Plan Investment Board Adds $65M in Abbott Laboratories ($ABT)
The Canada Pension Plan Investment Board increased its stake in Abbott Laboratories by 36%, adding 691,435 shares.
Key Points
- The Canada Pension Plan Investment Board increased its Abbott Laboratories holdings by 691,435 shares, reaching a total of 2,588,711 shares valued at about $241.7 million.
- Abbott Laboratories, trading at $93.35 on Friday, has a market cap of around $162.4 billion and a forward P/E of 15.39.
- Insiders have been actively buying shares, and analysts maintain a 'buy' consensus with a mean target price of $116.54.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
The Canada Pension Plan Investment Board has increased its stake in Abbott Laboratories (NYSE:ABT) by a significant 36.4%. The fund added 691,435 shares, bringing its total holdings to 2,588,711 shares, valued at approximately $241.7 million. This information comes from the latest 13F filing with the SEC, reflecting positions as of the reporting period.
Canada Pension Plan Investment Board vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Canada Pension Plan's Abbott Laboratories Position
The Canada Pension Plan Investment Board boosted its investment in Abbott Laboratories by 36.4%, raising its share count from 1,897,276 to 2,588,711. The additional 691,435 shares now account for a total value of about $241.7 million.
Other Institutional Activity in Abbott Laboratories
Institutional investors have been actively adjusting their positions in Abbott Laboratories. BlackRock, Inc. reduced its holdings by 1,221,310 shares, now owning 145,687,458 shares worth approximately $14.96 billion, marking a 0.8% decrease. Vanguard Capital Management LLC opened a new position with 112,949,933 shares valued at about $11.60 billion. State Street Corp trimmed its stake by 278,314 shares, holding 79,575,468 shares valued at roughly $8.17 billion, a 0.3% decrease. Capital Research Global Investors increased its holdings by 10,606,123 shares, a 27.1% rise, ending with 49,775,362 shares valued at $5.11 billion. Charles Schwab Investment Management Inc significantly increased its position by 32,310,527 shares, a 245% boost, now holding 45,500,055 shares worth about $4.67 billion.
Abbott Laboratories Stock Down 16.3%
Shares of Abbott Laboratories traded near $93.35 on Friday. The company has a market cap of approximately $162.4 billion and trades with a P/E ratio of 26.12 and a forward P/E of 15.39. Abbott's beta is 0.62, indicating lower volatility compared to the market. Over the past 52 weeks, the stock has ranged from a low of $81.97 to a high of $137.49. The 50-day moving average is $89.27, and the 200-day moving average is $112.80. Abbott maintains a current ratio of 1.39 and a quick ratio of 0.84, with a debt-to-equity ratio of 64.77.
$ABT stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Abbott Laboratories reported revenue of $45.13 billion with a growth rate of 7.8%. The company's earnings per share (EPS) was $3.57, with a net margin of 13.9% and a return on equity (ROE) of 12.3%. The next earnings report is expected on July 16, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Abbott Laboratories pays an annual dividend of $2.52 per share, yielding 2.7%. Its dividend payout ratio stands at 67.2%.
Insider Buying and Selling at Abbott Laboratories
Recent insider activity at Abbott Laboratories includes several purchases. On May 7, 2026, John Stratton bought 2,000 shares at an average price of $86.82. On April 28, 2026, Executive Vice President Mary Moreland acquired 5,314 shares at $94.41. Daniel Starks bought 10,000 shares at $92.65 on April 27, 2026, and also purchased 7,105 shares on April 24, 2026, without a disclosed price. Nita Ahuja and Sally Blount each acquired 2,286 shares on April 24, 2026, with no price specified.
Analysts Set New Price Targets
Analyst activity has been positive for Abbott Laboratories. On June 22, 2026, Piper Sandler reiterated its 'buy' rating and set a price target of $115. Barclays maintained its 'buy' rating with a $143 target on April 20, 2026. Other firms like Oppenheimer, RBC Capital, and Benchmark have also maintained 'buy' ratings with targets ranging from $115 to $130. The consensus among analysts is a 'buy', with a mean target price of $116.54 based on 24 opinions.
About Abbott Laboratories
Abbott Laboratories, headquartered in Abbott Park, Illinois, is a global healthcare company. It develops and sells a wide range of healthcare products, including pharmaceuticals, diagnostic equipment, nutritional products, and medical devices. The company operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Led by CEO Philip P. Boudreau, Abbott employs approximately 122,000 people worldwide.
Bottom Line
The Canada Pension Plan Investment Board's decision to significantly increase its stake in Abbott Laboratories signals a strong interest in the company's growth potential. Abbott's diversified healthcare offerings and solid financial performance make it a key player in the medical devices sector. As with all 13F filings, this data is historical and may not reflect the fund's current position.
Get Abbott Laboratories alerts
New 13F filings, insider trades, and analyst moves on $ABT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.